# A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)

> **NCT07350850** · PHASE2 · RECRUITING · sponsor: **Tongji Hospital** · enrollment: 110 (estimated)

## Conditions studied

- PCNSL
- Primary Central Nervous System Lymphoma

## Interventions

- **DRUG:** Pirtobrutinib, Sintilimab, Rituximab, Methotrexate
- **DRUG:** Standard of Care (Investigator Selected)

## Key facts

- **NCT ID:** NCT07350850
- **Lead sponsor:** Tongji Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-12-25
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-06-30
- **Target enrollment:** 110 (ESTIMATED)
- **Last updated:** 2026-03-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07350850

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07350850, "A Multicenter Two-Cohort Study of Methotrexate, Rituximab, Sintilimab and Pirtobrutinib for Treatment-Naive PCNSL vs. Real-World Investigator-Selected Treatment (Observational Cohort)". Retrieved via AI Analytics 2026-06-29 from https://api.ai-analytics.org/clinical/NCT07350850. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*